Peritoneal carcinomatosis, a cancer
that invades the abdominal cavity
Relapses
More than 75% of relapses
within 5 years
within 5 years
Incidence
+200 000 new cases / year
in EU
in EU
Survival rate
50% of cases do not survive
5 years
A fluorescent probe to assist the surgeon & maximize the completeness of tumor resection
Specific detection of tumor tissue
Tumor tissue is specifically detected through a glycosidic biomarker expressed by 90% of carcinoma (epithelial cancers). This biomarker is masked or invisible on healthy tissue. Our innovative probe makes it possible to discriminate between malignant and healthy tissue.
Administration mode
The nanoprobe is injected intraperitoneally in order to reach all nodules within the abdominal cavity even non-vascularized ones. These microscopic nodules are often responsibles for many relapses observed in those pathologies.
Detection of tumor microenvironment
Tumors' detection is made through accumulation of cancer-associated immune cells expressing CD176 (glycosidic biomarker) around the tumor tissue. Microscopic nodules' detection is possible even at their earliest development stages.
© Copyright 2024 see2cure
Diagnostic probe for fluorescence-guided surgery
Highlighting tumor of all sizes
to prevent relapse of abdominal cancers
They support us
Emerging from a primary tumor site (ovaries, colon, pancreas, etc.), cancer cells spread through the peritoneal cavity resulting in peritoneal carcinomatosis (aka generalized abdominal cancers)
Meet the team
Mathilde Coustets, PhD
Chief Executive Officer
& Cofounder
Laurent Paquereau, PhD, HDR
Chief Scientific Officer
& Cofounder
Gwenael Ferron, MD, PhD, HDR
Chief Medical Officer
& Cofounder
Your privacy is very important to us. We will collect and use personal information solely with the objective of responding to your online request.
Contact us
